StocksFundsScreenerSectorsWatchlists
URGN

URGN - UroGen Pharma Ltd Stock Price, Fair Value and News

15.14USD+1.89 (+14.26%)Market Closed

Market Summary

URGN
USD15.14+1.89
Market Closed
14.26%

URGN Alerts

  • 1 major insider sales recently.

URGN Stock Price

View Fullscreen

URGN RSI Chart

URGN Valuation

Market Cap

516.6M

Price/Earnings (Trailing)

-5.05

Price/Sales (Trailing)

6.25

EV/EBITDA

-5.33

Price/Free Cashflow

-6.75

URGN Price/Sales (Trailing)

URGN Profitability

Operating Margin

88.68%

EBT Margin

-118.87%

Return on Equity

156.79%

Return on Assets

-57.34%

Free Cashflow Yield

-14.82%

URGN Fundamentals

URGN Revenue

Revenue (TTM)

82.7M

Rev. Growth (Yr)

30.06%

Rev. Growth (Qtr)

12.84%

URGN Earnings

Earnings (TTM)

-102.2M

Earnings Growth (Yr)

9.88%

Earnings Growth (Qtr)

-18.91%

Breaking Down URGN Revenue

Last 7 days

11.3%

Last 30 days

-13.3%

Last 90 days

3.8%

Trailing 12 Months

53.7%

How does URGN drawdown profile look like?

URGN Financial Health

Current Ratio

5.42

Debt/Equity

-1.51

Debt/Cashflow

-0.78

URGN Investor Care

Shares Dilution (1Y)

33.68%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202368.0M72.5M77.3M82.7M
202254.1M57.7M62.4M64.4M
202119.3M31.9M39.8M48.0M
20207.2M8.8M10.3M11.8M
201902.7M4.2M5.7M
20188.6M9.0M1.5M1.1M
201715.2M12.8M10.5M8.2M
201600017.5M

Tracking the Latest Insider Buys and Sells of UroGen Pharma Ltd

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 18, 2024
schoenberg mark
sold
-168,600
14.05
-12,000
chief medical officer
Feb 01, 2024
schoenberg mark
sold
-59,790
15.78
-3,789
chief medical officer
Feb 01, 2024
smith jason drew
sold
-78,789
15.78
-4,993
general counsel
Jan 31, 2024
schoenberg mark
acquired
-
-
6,666
chief medical officer
Jan 31, 2024
kim dong
acquired
-
-
3,333
chief financial officer
Jan 31, 2024
smith jason drew
acquired
-
-
10,000
general counsel
Jan 31, 2024
schoenberg mark
sold
-59,638
15.74
-3,789
chief medical officer
Jan 31, 2024
smith jason drew
sold
-78,589
15.74
-4,993
general counsel
Aug 31, 2023
smith jason drew
sold
-68,438
18.01
-3,800
general counsel

1–10 of 50

Which funds bought or sold URGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 05, 2024
GAMMA Investing LLC
new
-
300
300
-%
Apr 05, 2024
NBC SECURITIES, INC.
new
-
6,000
6,000
-%
Apr 05, 2024
CWM, LLC
new
-
1,000
1,000
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
new
-
15.00
15.00
-%
Mar 11, 2024
VANGUARD GROUP INC
added
52.55
992,190
2,558,980
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
325
2,675,040
3,426,630
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
38.46
66,007
202,815
-%
Feb 22, 2024
SIERRA SUMMIT ADVISORS LLC
new
-
217,725
217,725
0.06%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
sold off
-100
-143,000
-
-%
Feb 15, 2024
BARCLAYS PLC
added
992
512,000
560,000
-%

1–10 of 45

Are Funds Buying or Selling URGN?

Are funds buying URGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own URGN
No. of Funds

Unveiling UroGen Pharma Ltd's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 22, 2024
arkin moshe
4.44%
1,369,315
SC 13D/A
Feb 14, 2024
rtw investments, lp
5.6%
1,726,808
SC 13G
Feb 14, 2024
menora mivtachim holdings ltd.
7.46%
2,303,031
SC 13G/A
Feb 14, 2024
ra capital management, l.p.
9.99%
3,083,558
SC 13G/A
Feb 14, 2024
great point partners llc
8.49%
2,620,545
SC 13G/A
Feb 13, 2024
stonepine capital management, llc
0%
0
SC 13G/A
Feb 02, 2024
blackrock inc.
5.6%
1,719,304
SC 13G
Dec 29, 2023
ra capital management, l.p.
9.99%
3,083,550
SC 13G
Sep 15, 2023
great point partners llc
8.51%
2,620,545
SC 13G
Aug 04, 2023
monograph capital holdings advisors, llc
5.1%
1,572,327
SC 13D

Recent SEC filings of UroGen Pharma Ltd

View All Filings
Date Filed Form Type Document
Mar 20, 2024
4
Insider Trading
Mar 18, 2024
144
Notice of Insider Sale Intent
Mar 14, 2024
10-K
Annual Report
Mar 14, 2024
8-K
Current Report
Mar 04, 2024
8-K
Current Report
Mar 01, 2024
8-K
Current Report
Feb 22, 2024
SC 13D/A
13D - Major Acquisition
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to UroGen Pharma Ltd)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
-1.24% -34.47%
-8.53
5.87
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.7B
1.8B
0.05% -28.38%
-42.48
10.23
76.23% 61.08%
17.4B
2.4B
8.82% -6.19%
103.82
7.19
15.42% 18.43%
12.1B
3.7B
-8.57% -28.49%
20.24
3.27
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.73% -34.59%
-11.81
15.74
425.83% 18.94%
4.7B
-
-4.69% 71.46%
-7.23
60.35
54.84% -34.79%
3.3B
270.6M
-0.99% 6.40%
-13.71
12.12
440.80% -27.84%
3.1B
240.7M
-13.54% -18.95%
-10.32
12.72
-1.03% -92.09%
2.8B
726.4M
-12.42% -7.51%
-46.06
3.89
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-8.48% -15.36%
25.1
4.5
85.90% -14.05%
599.0M
983.7M
-18.48% -55.04%
-1.1
0.61
-50.36% 17.16%
428.3M
881.7K
-13.30% 407.71%
-9.6
466.16
-77.61% -5.33%
257.8M
4.9M
-1.96% -2.22%
-1.91
52.97
-54.97% 51.72%
7.2M
2.1M
77.59% 88.99%
-0.26
2.14
-13.45% 66.37%

UroGen Pharma Ltd News

Latest updates
Yahoo Finance17 hours ago
Seeking Alpha14 Mar 202407:00 am
StockNews.com01 Mar 202408:00 am
The Motley Fool8 months ago

UroGen Pharma Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q42018Q3
Revenue12.8%23,530,00020,852,00021,139,00017,192,00018,092,00016,097,00016,604,00013,564,00016,174,00011,351,00013,032,0007,485,0007,966,0003,461,000372,000297,600223,200148,80074,400-283,000
Cost Of Revenue-3.4%2,286,0002,367,0002,443,0002,265,0002,263,0002,020,0001,846,0001,525,0001,589,0001,244,0001,427,000897,000652,000309,00048,000-----1,055,000
Gross Profit14.9%21,244,00018,485,00018,696,00014,927,00015,829,00014,077,00014,758,00012,039,00014,585,00010,107,00011,605,0006,588,0007,314,0003,152,000324,000---18,000--772,000
  S&GA Expenses12.9%24,551,00021,755,00022,494,00024,474,00021,634,00019,071,00020,833,00021,300,00021,418,00021,624,00022,304,00022,189,00022,163,00022,065,00024,018,00021,973,00019,745,00013,972,00013,775,00012,552,00010,743,000
  R&D Expenses10.5%11,302,00010,230,00011,584,00012,498,00014,477,00013,093,00012,640,00012,696,00013,082,00011,923,00012,124,00010,513,00012,405,00010,211,0008,106,00016,588,00020,094,0009,481,0009,996,00011,465,0009,574,000
EBITDA Margin11.9%-1.18-1.34-1.47-1.61-1.66-1.70-1.93-2.04-2.26-2.72-3.36-5.85-10.57--------
Income Taxes42922.2%3,854,000-9,00054,00021,000689,000709,00032,000325,0001,137,000-312,000-3,374,000--------
Earnings Before Taxes-1.3%-22,162,000-21,888,000-24,082,000-30,192,000-28,180,000-25,122,000-26,659,000-28,067,000-27,315,000-30,211,000-25,910,000-25,935,000-27,152,000-28,816,000-31,349,000------
EBT Margin12.0%-1.19-1.35-1.48-1.62-1.68-1.72-1.95-2.06-2.28-2.74-3.38-5.87-10.60--------
Net Income-18.9%-26,016,000-21,879,000-24,136,000-30,213,000-28,869,000-25,831,000-26,691,000-28,392,000-28,452,000-30,211,000-26,222,000-25,935,000-30,526,000-28,816,000-31,349,000-37,793,000-38,973,000-22,252,000-22,477,000-23,716,000-20,533,000
Net Income Margin9.1%-1.24-1.36-1.50-1.64-1.71-1.75-1.97-2.09-2.31-2.83-3.49-6.05-10.89--------
Free Cashflow25.0%-13,052,000-17,399,000-20,289,000-25,830,000-21,765,000-17,765,000-24,262,000-24,021,000-20,272,000-18,670,000-19,014,000-27,688,000-21,414,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-7.9%17819495.0011313612814616612013515497.00122140161167202227239252104
  Current Assets-7.1%16918281.0096.0012912214016111412514093.00116129130122149160191248102
    Cash Equivalents-20.4%95.0011920.0037.0055.0029.0081.0010544.0055.0063.0040.0053.0025.0036.0026.0050.0066.0090.00247101
  Inventory13.4%6.005.005.005.004.005.005.005.005.004.003.003.002.001.001.00------
  Net PPE-16.3%1.001.001.001.001.002.002.002.002.002.002.002.002.002.001.001.001.001.001.001.001.00
Liabilities3.4%24423623423022519218718311110397.0021.0026.0019.0018.0016.0022.0016.0014.0012.0013.00
  Current Liabilities21.0%31.0026.0027.0025.0024.0019.0018.0019.0022.0020.0019.0017.0021.0018.0016.0014.0019.0014.0012.0010.0013.00
  Long Term Debt-100.0%-99.0098.0098.0098.0072.0071.0071.00-------------
    LT Debt, Non Current0.0%99.0099.0098.0098.0098.0072.0071.0071.00-------------
Shareholder's Equity-Infinity%-65.21----89.36---8.0032.0056.0076.0096.0012114315018021122524090.00
  Retained Earnings-4.0%-679-653-631-607-577-548-522-495-467-438-408-382-356-326-297-265-228-189-166-144-122
  Additional Paid-In Capital0.4%614611493491488485481479476470465459453446439416408400391384213
Shares Outstanding5.3%32.0031.0024.0023.0023.0023.0023.0023.0022.0022.0022.0022.0022.00--------
Float-------145---251---525---695--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations24.9%-12,996-17,299-20,274-25,807-21,752-17,612-24,199-23,996-20,070-18,476-18,945-27,401-21,242-25,080-23,929-35,635-26,000-12,528-14,555-17,934-10,284
  Share Based Compensation17.4%2,6112,2242,2222,2862,3682,4402,8232,9495,3575,5156,0466,1956,5266,7637,1197,6178,0657,2437,2127,4478,877
Cashflow From Investing-2928.9%-11,3444013,7206,27023,108-35,493-15113,5969,12510,660-30,74015,02449,46513,23417,51413,0259,296-12,659-142,186-44.00-26.00
Cashflow From Financing-100.0%40.00116,07714367125,3681,101-77.0070,742-32.00-16872,5154.0078.0061.0016,29890.002451,126373163,5062,200

URGN Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Revenue$ 82,713$ 64,357
Cost of revenue9,3617,654
Gross profit73,35256,703
Operating expenses:  
Research and development expenses45,61452,906
Selling, general and administrative expenses93,27482,838
Operating loss(65,536)(79,041)
Financing on prepaid forward obligation(21,552)(21,559)
Interest expense on long-term debt(14,715)(8,438)
Interest and other income, net3,4791,010
Loss before income taxes(98,324)(108,028)
Income tax expense(3,920)(1,755)
Net Loss(102,244)(109,783)
Statements of Comprehensive Loss  
Net loss(102,244)(109,783)
Other comprehensive income (loss)  
Unrealized gain (loss) on investments119(82)
Comprehensive Loss$ (102,125)$ (109,865)
Net loss per ordinary share - basic and diluted (in dollars per share)$ (3.55)$ (4.81)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)28,834,30322,806,812

URGN Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 95,002$ 55,408
Marketable securities41,96644,556
Restricted cash821813
Accounts receivable15,44312,704
Inventories5,6734,325
Prepaid expenses and other current assets10,28111,101
Total current assets169,186128,907
Non-current assets:  
Property and equipment, net6891,297
Restricted deposit225223
Right-of-use assets1,6712,452
Marketable securities4,5020
Other non-current assets2,0382,740
Total Assets178,311135,619
Current liabilities:  
Accounts payable and accrued expenses16,53812,383
Employee related accrued expenses10,8148,257
Other current liabilities3,8603,276
Total current liabilities:31,21223,916
Non-current liabilities:  
Prepaid forward obligation109,72298,923
Long-term debt98,55197,537
Long-term lease liabilities8441,586
Uncertain tax positions liability3,1943,018
Total Liabilities243,523224,980
Commitments and Contingencies (Note 19)
Shareholders' Deficit:  
Ordinary shares, NIS 0.01 par value; 100,000,000 shares authorized at December 31, 2023 and 2022; 32,490,119 and 23,129,953 shares issued and outstanding as of December 31, 2023 and 2022, respectively8963
Additional paid-in capital614,035487,787
Accumulated deficit(679,348)(577,104)
Accumulated other comprehensive income (loss)12(107)
Total Shareholders' Deficit(65,212)(89,361)
Total Liabilities and Shareholders' Deficit$ 178,311$ 135,619
URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
 CEO
 WEBSITEurogen.com
 INDUSTRYBiotechnology
 EMPLOYEES193

UroGen Pharma Ltd Frequently Asked Questions


What is the ticker symbol for UroGen Pharma Ltd? What does URGN stand for in stocks?

URGN is the stock ticker symbol of UroGen Pharma Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of UroGen Pharma Ltd (URGN)?

As of Fri Apr 12 2024, market cap of UroGen Pharma Ltd is 516.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of URGN stock?

You can check URGN's fair value in chart for subscribers.

What is the fair value of URGN stock?

You can check URGN's fair value in chart for subscribers. The fair value of UroGen Pharma Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of UroGen Pharma Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for URGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is UroGen Pharma Ltd a good stock to buy?

The fair value guage provides a quick view whether URGN is over valued or under valued. Whether UroGen Pharma Ltd is cheap or expensive depends on the assumptions which impact UroGen Pharma Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for URGN.

What is UroGen Pharma Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 12 2024, URGN's PE ratio (Price to Earnings) is -5.05 and Price to Sales (PS) ratio is 6.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. URGN PE ratio will change depending on the future growth rate expectations of investors.